Effects of NADH on dopamine release in rat striatum

Synapse

Volumn 36, Issue 2, 2000, Pages 95-101

  Pearl, Sandra M ^a   Antion, Marcia D ^a   Stanwood, Gregg D ^a   Jaumotte, Juliann D ^a   Kapatos, Gregory ^b   Zigmond, Michael J ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

NADH; Parkinson's disease; Tetrahydrobiopterin

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; DOPAMINE; POTASSIUM CHLORIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; TETRAHYDROBIOPTERIN; TYROSINE 3 MONOOXYGENASE;

ANIMAL TISSUE; ARTICLE; CORPUS STRIATUM; DOPAMINE RELEASE; DRUG EFFECT; DRUG EFFICACY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SYNAPTOSOME;

ANIMALS; ANTIOXIDANTS; BIOPTERIN; CELL CULTURE TECHNIQUES; DOPAMINE; EXTRACELLULAR SPACE; MALE; NAD; NEOSTRIATUM; PARKINSON DISEASE; POTASSIUM CHLORIDE; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS;

EID: 0034085740     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2396(200005)36:2<95::AID-SYN2>3.0.CO;2-U     Document Type: Article

References (38)

1. Abercrombie ED, Bonatz AE, Zigmond MJ. 1990. Effects of L-DOPA on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats. Brain Res 525:36-44.
2. Agid Y, Javoy F, Glowinski J. 1973. Hyperactivity of remaining dopaminergic neurons after partial destruction of the nigro-striatal dopaminergic system in the rat. Nature 245:150-151.
3. Anastasiadis PZ, Kuhn DM, Levine RA. 1994. Tetrahydrobiopterin uptake into rat brain synaptosomes, cultured PC12 cells, and rat striatum. Brain Res 665:77-84.
4. Berman SB, Zigmond MJ, Hastings TG. 1997. Modification of dopamine transporter function: effect of reactive oxygen species and dopamine. J Neurochem 69:1185-1195.
5. Birkmayer GJD, Birkmayer W. 1989a. Stimulation of endogenous L-dopa biosynthesis - a new principle for the therapy of Parkinson's disease. Acta Neurol Scand 126:183-187.
6. Birkmayer W, Birkmayer GJD. 1989b. Nicotineamideadeninedinucleotide (NADH): The new approach in the therapy of Parkinson's disease. Ann Clin Lab Sci 19:38-43.
7. Birkmayer W, Riederer P. 1983. Parkinson's disease: biochemistry, clinical pathology, and treatment. New York: Springer-Verlag. p 43.
8. Birkmayer JGD, Vrecko C, Volc D, Birkmayer W. 1993. Nicotineamide adenine dinucleotide (NADH): a new therapeutic approach to Parkinson's disease, comparison of oral and parenteral application. Acta Neurol Scand 87: Suppl 146:32-35.
9. Bradford MM. 1976. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
10. Brenneman AR, Kaufman S. 1964. The role of tetrahydrobiopterin in the enzymatic conversion of tyrosine to 3,4-dihydroxyphenylalanine. Biochem Biophys Res Comm 17:177-183.
11. Dizdar N, Kagedal B, Lindvall B. 1994. Treatment of Parkinson's disease with NADH. Acta Neurol Scand 90:345-347.
12. Fukushima, T, Nixon JC. 1980. Analysis of reduced forms of biopterin in biological tissues and fluids. Analyt Biochem 102:176-188.
13. Hefti F, Melamed E, Wurtman RJ. 1980. Partial lesions of the dopaminergic nigrostriatal system in rat brain: biochemical characterization. Brain Res 195:123-127.
14. Kapatos G, Katoh S, Kaufman S. 1982. Biosynthesis of biopterin by rat brain. J Neurochem 39:1152-1162.
15. Koshimura K, Miwa S, Lee K, Fujiwara M, Watanabe Y. 1990. Enhancement of dopamine release in vivo from the rat striatum by dialytic perfusion of 6R-L-erythro-5,6,7,8-tetrahydrobiopterin. J Neurochem 54:1391-1397.
16. Koshimura K, Takagi Y, Miwa S, Kido T, Watanabe Y, Murakami Y, Kato Y, Masaki T. 1995. Characterization of a dopamine-releasing action of 6 R-L-erythro-tetrahydrobiopterin: Comparison with a 6S-form. J Neurochem 65:827-830.
17. Koshimura K, Tanaka J, Murakami Y, Kato Y. 1998. Enhancement of neuronal survival by 6R-tetrahydrobiopterin. Neuroscience 88:561-569.
18. Kuhn W, Müller T, Winkel R, Danielcziek S, Gerstner A, Häcker R, Mattern C, Przuntek H. 1996. Parenteral application of NADH in Parkinson's disease: clinical improvement partially due to stimulation of endogenous levodopa synthesis. J Neural Transm 103:1187-1193.
19. Liang LP, Kaufman S. 1998. The regulation of dopamine release from striatum slices by tetrahydrobiopterin and L-arginine-derived-nitric oxide. Brain Res 800:181-186.
20. +'-independent dopamine release from striatal slices: A possible role of reverse dopamine transport. J Pharm Exp Ther 256:1132-1138.
21. McGeer PL, McGeer EG, Wada JA. 1971. Distribution of tyrosine hydroxylase in human and animal brain. J Neurochem 18:1647.
22. Nagatsu T, Namaguchi T, Kato T, Sugimoto T, Matsura S, Akino M, Iizuka R, Narabayashi H. 1981. Biopterin in human brain and urine from controls and parkinsonian patients: application of a new radioimmunoassay. Clin Chim Acta 109:309-311.
23. Nomura Y, Yotsumoto I, Segawa T. 1981. Ontogenetic development of high potassium- and acetycholine-induced release of dopamine from striatal slices of the rat. Brain Res 227:171-177.
24. Parsons LH, Justice JB Jr. 1993. Perfusate serotonin increases extracellular dopamine in the nucleus accumbens as measured by in vivo microdialysis. Brain Res 606:195-199.
25. 3H] dopamine from rat striatal slices. Brain Res 157:391-395.
26. Schwarz RD, Uretsky NJ, Bianchine JR. 1980. The relationship between the stimulation of dopamine synthesis and release produced by amphetamine and high potassium in striatal slices. J Neurochem 35:1120-1127.
27. Shen R-S, Zhang Y. 1991. Antioxidant activity of tetrahydrobiopterin in pheochromocytoma PC 12 cells. Chem-Biol Interact 78:307-319.
28. Snyder GL, Zigmond MJ. 1990. The effects of L-DOPA on in vitro dopamine release from striatum. Brain Res 508:181-187.
29. Snyder GL, Keller RW Jr., Zigmond MJ. 1990. Dopamine efflux from striatal slices after intracerebral 6-OHDA: evidence for compensatory hyperactivity of residual terminals. J Pharm Exp Ther 253: 867-876.
30. Stachowiak MK, Keller RW Jr, Stricker EM, Zigmond MJ. 1987. Increased dopamine efflux from striatal slices during development and after nigrostriatal bundle damage. J Neurosci 7:1648-1654.
31. Swerdlow RH. 1998. Is NADH effective in the treatment of Parkinson's Disease? Drugs and Aging 13:263-268.
32. Tsukada H, Lindner K-J, Hartvig P, Långström B. 1994. Effect of 6R-L-erythro-5,6,7,8-tetrahydrobiopterin on the extracellular levels of dopamine and serotonin in the rat striatum: a microdialysis study with tyrosine or tryptophan infusion. Brain Res 635:59-67.
33. Vrecko K, Birkmayer GJD, Krainz J. 1993. Stimulation of dopamine biosynthesis in cultured PC 12 phaeochromocytoma cells by the coenzyme nicotineamide adenine dinucleotide (NADH). J Neural Transm [P-D Section] 5:147-156.
34. Vrecko K, Storga D, Birkmayer JD, Moller R, Tafeit E, Horejsi R, Reibnegger G. 1997. NADH stimulates endogenous dopamine biosynthesis by enhancing the recycling of tetrahydrobiopterin in rat phaeochromocytoma cells. Biochim Biophys Acta 1361:59-65.
35. Weihmuller FB, Ulas J, Nguyen L, Cotman CW, Marshall JF. 1992. Elevated NMDA receptors in Parkinsonian striatum. NeuroReport 3:977-980.
36. 3H]dopamine. Neuropharmacology 29:475-486.
37. Zigmond MJ, Acheson AL, Stachowiak MK, Stricker EM. 1984. Neurochemical compensation after nigrostriatal bundle injury in an animal model of preclinical Parkinsonism. Arch Neurol 41:856-861.
38. Zigmond MJ, Stricker EM. 1977. Behavioral and neurochemical effects of central catecholamine depletion: A possible model for "subclinical" brain damage. In: Hanin I, Usdin E, editors. Animal models in psychiatry and neurology. New York: Pergamon Press. p 415-429.